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SEC23B gene encodes an essential component of the coat protein complex II (COPII)-coated vesicles. Muta-
tions in this gene cause the vast majority the congenital dyserythropoietic anemia Type II (CDA II), a rare
disorder resulting from impaired erythropoiesis. Here, we investigated 28 CDA II patients from 21 unrelated
families enrolled in the CDA II International Registry. Overall, we found 19 novel variants [c.2270 A>C
p.H757P; c.214922A >G; c.110911G >A; c.387(delG) p.L129LfsX26; c.1858 A>G p.M620V; c.1832 G>C
p.R611P; c.1735 T>A p.Y579N; c.1254 T>G p.I418M; c.1015 C>T p.R339X; c.1603 C>T p.R535X; c.1654 C>T
p.L552F; c.1307 C>T p.S436L; c.27913A >G; c. 2150(delC) p.A717VfsX7; c.1733 T>C p.L578P; c.110915
G>A; c.221131 A>G; c.367 C>T p.R123X; c.1857_1859delCAT; p.I619del] in the homozygous or the com-
pound heterozygous state. Homozygosity or compound heterozygosity for two nonsense mutations was
never found. In four cases the sequencing analysis has failed to ﬁnd two mutations. To discuss the putative
functional consequences of missense mutations, computational analysis and sequence alignment were per-
formed. Our data underscore the high allelic heterogeneity of CDA II, as the most of SEC23B variations are
inherited as private mutations. In this mutation update, we also provided a tool to improve and facilitate the
molecular diagnosis of CDA II by deﬁning the frequency of mutations in each exon. Am. J. Hematol.
85:915–920, 2010. V V C 2010 Wiley-Liss, Inc.
Introduction
Mutations in the SEC23B gene (Sec23 homolog B; MIM#
610512, 20p11.23) cause the vast majority of the congeni-
tal dyserythropoietic anemia Type II (CDA II MIM#
%224100), an autosomal recessive disorder that represents
the most common form of CDAs. Like other forms, it is
characterized by a mild to moderate lifelong anemia, inef-
fective erythropoiesis, and morphologic abnormalities of
mature red blood cells (RBC) and their precursors [1].
Splenomegaly and jaundice are the most evident clinical
signs [2,3]. About 10% of patients require frequent transfu-
sions or are dependent on them. Until now, it has not been
possible to establish whether these cases are due to more
severe mutations or whether they are due to other gene(s)
causing the same phenotype, or to the interaction with
other intra-erythrocytic defects, such as thalassemia [4].
CDA II is associated with the presence in the bone mar-
row of bi- or multinucleated late erythroid precursors, kar-
yorrhexis, and pseudo-Gaucher cells. Diagnosis was, for a
long time, achieved by bone marrow examination. It shows
5–10 times more erythroblasts than normal (erythroid
hyperplasia) [1,3]; early erythroblasts are relatively normal,
but more than 10% of all erythroid cells are binucleated
with equal size of two nuclei or multinucleated [5]. Exten-
sive morphological anomalies of CDA-II erythroblastic cells
were observed using electron microscopy (EM), with the
most signiﬁcant being the presence of the so-called double
membrane, which is observable in mature RBCs as well
[6,7]. This typical aspect is due to residual endoplasmic
reticulum [8]. Polyacrylamide gel electrophoresis in pres-
ence of sodium dodecyl sulphate (SDS-PAGE) revealed the
presence of a thinner band 3 with an increased anodic mo-
bility due to reduced glycosylation. This cardinal abnormal-
ity represents a key for the diagnosis [9] and could suggest
a defect in vesicles trafﬁcking.
SEC23B is an essential component of coat protein com-
plex II (COPII)-coated vesicles that transport secretory pro-
teins from the endoplasmic reticulum (ER) to the Golgi
complex. In Saccharomyces cerevisiae this complex is well
ﬁne characterized: the coat comprises ﬁve subunits, the
small GTPase Sar1 (Secretion associated, ras-related), the
Sec23–Sec24 ‘‘inner coat’’ complex, and the Sec13–Sec31
‘‘outer coat’’ complex. Sec23 is a GTPase-activating protein
(GAP) that activates Sar1 [10], and the outer coat is re-
sponsible for stimulating this GAP-activity. Therefore, full
assembly of the coat stimulates Sar1 GTP-hydrolysis activ-
ity [11]. This enables the coat to depolymerise and be
recycled for another round of vesicle biogenesis.
The SEC23B gene spans  54 kb on human chromo-
some 20p11.23 and is composed of 20 exon regions codi-
fying 767 residues arranged in ﬁve functional domains: zinc
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domain interacts with at least one of three coat subunits, in
particular, trunk domain is linked by Sec24, Sar1, and
Sec31, gelsolin domain is linked by Sar1 and Sec31, and
other three domains are linked only by Sec31.
To date, 34 causative mutations in SEC23B gene were
described [12–15]. In this work, we described 19 novel
variants localized along the entire coding sequence (eight
missense, two frameshift, three nonsense, ﬁve splicing
mutations, and one small deletion). This is the ﬁrst update
of SEC23B mutations involved in CDA II. Moreover, we
attempted to characterize the putative effects of the amino
acid substitutions on protein structure or function, as well
as on mRNA stability by using bioinformatic analyses; we
also tried to deﬁne the effect of mutations near splice site
on mRNA processing alteration by using the same
approaches. Finally, by deﬁning the frequency of muta-
tions and those of mutated alleles in each exon, we pro-
vided a powerful tool to improve the molecular diagnosis
of CDA II.
Methods
Inclusion criteria and deﬁnition of the cohort used for mutational analy-
sis. Twenty-eight CDA II patients (15 males and 13 females) from 21
unrelated families enrolled in the CDA II International Registry were
investigated (Supporting Information Table Is). The diagnosis of CDA II
was based on the presence of mild to moderate anemia, ineffective
erythropoiesis, and morphological abnormalities of the erythroblasts in
the bone marrow. Conﬁrmation of the diagnosis was made by mutation
screening of the SEC23B gene or at least one of the following analyses:
the revelation of the typical narrower band size and faster migration of
the band 3 and band 4.5 proteins at SDS-PAGE; the demonstration of
superﬁcial appearance of reticulum-endothelial proteins (calreticulin, glu-
cose regulated protein 78, protein disulphide isomerase) on membrane
proteins by Western blot (WB) analysis; the presence of a discontinuous
double membrane in mature erythroblasts by electron microscopy (EM) [5].
After signed informed consent, blood was obtained for genetic analysis
from the probands. Blood from healthy control subjects was obtained after
signed consent according to the Declaration of Helsinki. This project was
approved by local ethical committee (University Federico II).
Genomic mutational screening. Genomic DNA preparation, mutational
search, oligonucleotide primers design, and direct sequencing were
performed as previously described [14]. Sequence primers are avail-
able on request (achille.iolascon@unina.it). Nucleotide numbering
reﬂects cDNA numbering with 11 corresponding to the A of ATG trans-
lation initiation codon in the reference sequence (Ensembl transcript
ID: ENST00000377475). The initiation codon is codon 1.
In silico analyses. To perform a multiple sequence alignment, sequen-
ces homologous to human SEC23B were assembled in a multiple
sequence alignment using database UniProtKB release 15.0 of March
25, 2009; program NCBI BLASTP 2.0.12 on services.uniprot.org (http://
services.uniprot.org/blast/). The alignment is made using sequences
found in the Uniprot Knowledge-base. The aligned SEC23 sequences
were from the species: human (Accession No. Q15437), mouse
(Q9D662), Xenopus laevis (Q6DJE0), Danio rerio (Q6AZ98), Caeno-
rhabditis elegans (Q9U2Z1), Saccharomyces cerevisiae (B3LKE0). The
secondary structure of SEC23B protein was predicted by using Jpred,
a web server that takes a protein sequence and from this predicts
secondary structure using a neural network called Jnet (http://www.
compbio.dundee.ac.uk/www-jpred/). To localize the missense and non-
sense alterations within the protein domains of SEC23B, we submitted
the wild type protein sequence on ESyPred3D Web Server 1.0
(www.fundp.ac.be/sciences/biologie/urbm/bioinfo/esypred/). This tool imple-
ments a homology modeling approach followed by a ﬁnal analysis with
MODELLER release 4 to build a 3D model of the submitted protein [16].
This routine includes the satisfaction of spatial and geometric restraints
and a very fast dynamic annealing. The 3D structures were visualized
using the molecular-graphics software Yasara (www.yasara.org).
The possible impact of the amino acid substitution on the structure
or function of protein was predicted by using two bioinformatic tools
speciﬁcally designed for interpretation of missense variants: PolyPhen
(http: //genetics.bwh.harvard.edu/pph/and) [17] and PANTHER (http://
www.pantherdb.org/tools/csnpScoreForm.jsp). PolyPhen identiﬁes homo-
logues of the input sequence via BLAST search and computes the
absolute value of the difference between proﬁle scores of both allelic
variants in the mutated position. Big values of this difference (PSIC
score) may indicate that the studied substitution is rarely or never
observed in the protein family. For the input form, we used the protein
identiﬁer of SEC23B (Q15437) from the UniProt database. PANTHER
calculates the subPSEC (substitution position-speciﬁc evolutionary con-
servation) score based on an alignment of evolutionarily related pro-
teins. This score is the negative logarithm of the probability ratio of the
wild-type and mutant amino acids at a particular position. PANTHER
subPSEC scores are continuous values from 0 (neutral) to about 210
(most likely to be deleterious). Data from PANTHER can be used to
calculate the probability that a given variant will have a deleterious
effect on protein function (Pdeleterious): a subPSEC score of 23 corre-
sponds to a Pdeleterious of 0.5 [18].
To analyze the possible effect of the mutations near to 30 and 50
splice site junctions on splicing processing, we used a web server tool,
Splice Site Prediction by Neural Network (http: //www.fruitﬂy.org/seq_
tools/splice.html). The output of the network is a score between 0 and
1 for a potential splice site.
Secondary structures of the full-length SEC23B mRNA, either wild
type sequence that those mutated, were predicted by the program
GeneBee (http: //www.genebee.msu.su/genebee.html).
Frequency of the mutations assessment. The relative richness in
mutations (i) has been calculated by the ratio of the mutations falling in
each exon of SEC23B gene and the overall count of causative muta-
tions identiﬁed until now; similarly, the frequency of mutated alleles in
each exon (ii), by the ratio of the number of mutated alleles for each
exon and the overall count of mutated alleles. For the mutations near
to 30 and 50 splice site junctions, the exon ﬂanking splice junction has
been considered. The deﬁnition of ‘‘exon’’ includes about 200 bases
upstream and downstream ﬂanking the coding sequence.
Results
Patient’s phenotype
Clinical ﬁndings of all 28 affected individuals enrolled in
this study were shown in Supporting Information Table Is.
The mean age of onset symptoms was 3 years. The mean
Hb value was 10 g/dL before splenectomy, and mean ferri-
tin value was 303 lg/L. Mean reticulocyte absolute count at
diagnosis was 88797 3 10
6/L. Clinical data shown here are
indicative of a classical framework of CDA II; moreover,
they are compatible with those published before [14]. For
most of all patients SDS-PAGE revealed the typical nar-
rower band size and faster migration of the band 3
and band 4.5 proteins; the diagnosis has been also con-
ﬁrmed by the demonstration of superﬁcial appearance of
reticulum-endothelial protein GRP78 on membrane proteins
by WB.
Identiﬁcation of novel mutations of SEC23B gene in
CDA II patients
All enrolled patients were diagnosed at molecular level.
Almost all patients carried two mutations in the compound
heterozygous or homozygous state: only in four cases,
mutations were not identiﬁed in both alleles. We identiﬁed a
total of 19 novel different allelic variants (Table I) (Fig.
1A,B). Of these, eight were missense mutations: c.2270
A>C p.H757P, c.1832 G>C p.R611P, c.1858 A>G
p.M620V; c.1735 T>A p.Y579N, c.1254 T>G p.I418M,
c.1654 C>T p.L552F, c.1307 C>T p.S436L, c.1733 T>C
p.L578P; 3 were nonsense mutations: c.1015 C>T
p.R339X, c.1603 C>T p.R535X, c.367 C>T p.R123X; two
were frameshift mutations: c.387 (del G) p.L129LfsX26,
c.2150 (del C) p.A717VfsX7; 5 were splicing mutations:
c.214922A >G, c.110911G >A, c.27913A >G, c.110915
G>A, c.221131 A>G; only one consist of a deletion of a
codon: c.1857_1859delCAT p.I619del. The 3D model of the
protein has been built using the 3D structure 2NUP chain
‘‘A’’ (RCBS Protein Data Bank) as template. This template
shares 84.5% identities with our query sequence (Fig. 1A).
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changes were absent in normal subjects. Mutated positions
were mostly conserved in analyzed species from Homo
sapiens to yeast (Fig. 1B).
Evaluation of the causal role of mutations by in silico
analyses
We evaluated in silico the possible effect of amino acid
substitutions of the eight missense mutations by the empiri-
cally derived rules of PolyPhen tool. The effect of these
alterations on protein structure was predicted to be
‘‘probably damaging’’, i.e., they are with high conﬁdence
supposed to affect protein function or structure (Table I). By
using PANTHER tool, we partially conﬁrmed the predicted
functional signiﬁcance of almost all missense mutations:
only the M620V and the S436L variants are predicted to
affect minimally protein function (subPSEC 23.2 and
23.09, respectively) (Table I).
Moreover, two (c.1832 G>C p.R611P, c.1654 C>T
p.L552F) out of the eight missense mutations were pre-
dicted to alter the secondary structure of SEC23B mRNA
(GeneBee program) when compared to that predicted for
wild type sequence. Particularly, the free energy of
SEC23B mRNA was predicted to be affected in a different
manner by the two nucleotide substitution (2640.8 kcal/mol
for wild type allele; 2650.8 kcal/mol for c.1832 C allele;
2636.5 kcal/mol for c.1654 T allele) (Supporting Informa-
tion Fig. 1s, panels A-C-D). As positive control, we pre-
dicted also the secondary structure of c.325 A, the most
frequent mutated allele so far described in CDA II patients,
for which the free energy was predicted to be lower
(2631.3 kcal/mol) when compared to wild type sequence
(Supporting Information Fig. 1s, panel B). This observation
is consistent with published observation: in fact, E109K is
already associated with protein instability, with less than
5% of protein detectable compared to wild type [12].
Splice Site Prediction by Neural Network tool predicted a
donor splice site abolition for two out the ﬁve splice site
mutations, c.110911G >A and c.110915G >A, both falling
in intron between exon 3 and 4. Instead, for the mutation
c.221131 A>G was predicted the creation of a new donor
splice site with a high score (0.99). Finally, the mutation
c.27913A >G seems to induce only a limited score reduc-
tion of the predicted wild type donor site (from 1.00 to 0.95)
(Table I).
For only one splice site alteration, c.214922A >G, this
web server tool failed to predict the wild type acceptor
splice site. For this variant, we used another bioinformatic
tool, Gene Splicer (http: //www.cbcb.umd.edu/software/Gen-
eSplicer/gene_spl.shtml), whose prediction showed a mis-
localization of the acceptor splice site (upstream of two
positions) with a slight reduction of the score (from 6.5
to 6.3).
TABLE I. Mutations Detected in SEC23B
Patient ID Exon Intron
Nucleotide
change
a
Predicted effect on
coding sequence
b Effect on protein or mRNA
Functional
domains References
F29P1 4 325 G>A Glu109Lys <5% of WT expression Segment 2 [12]
20 2270 A>C His757Pro Probably damaging (3.488)
c (24.29/0.78)
d Segment 6 This study
F30P1 2 40 C>T Arg14Trp <5% of WT expression Segment 1 [12]
18–19 214922A >G – Gelsolin This study
F31P1 16 1858 A>G Met620Val Probably damaging (3.116)
c (23.21/0.55)
d Helical This study
16 1858 A>G Met620Val
F32P1 F32P2 2 40 C>T Arg14Trp <5% of WT expression Segment 1 [12]
9–10 1109 1 1G >A – Donor site abolition (0.93>–)
e Trunk This study
F33P1 18–19 214922A >G – Gelsolin This study
F34P1 F34P2 2 40 C>T Arg14Trp <5% of WT expression Segment 1 [12]
5 387 (delG) Leu129LeufsX26 Trunk This study
F35P1 F35P2 F35P3 2 40 C>T Arg14Trp <5% of WT expression Segment 1 [12]
16 1832 G>C Arg611Pro Probably damaging (2.504)
c (24.17/0.76)
d Helical This study
F36P1 2 40 C>T Arg14Trp <5% of WT expression Segment 1 [12]
15 1735 T>A Tyr579Asn Probably damaging (2.992)
c (24.64/0.84)
d Helical This study
F37P1 11 1254T>G Ile418Met Probably damaging (1.851)
c (23.87/0.71)
d b-sheet This study
F38P1 9 1015 C>T Arg339X Trunk This study
F39P1 F39P2 2 40 C>T Arg14Trp <5% of WT expression Segment 1 [12]
14 1603 C>T Arg535X Helical This study
F40P1 14 1654 C>T Leu552Phe Probably damaging (2.125)
c (24.12/0.75)
d Helical This study
F41P1 4 325 G>A Glu109Lys <5% of WT expression Segment 2 [12]
11 1307 C>T Ser436Leu Probably damaging (2.577)
c (23.09/0.52)
d b-sheet This study
F42P1 3–4 279 1 3A >G – Donor site alteration (1.00>0.95)
e Zink ﬁnger This study
4 325 G>A Glu109Lys <5% of WT expression Segment 2 [12]
F43P1 13 1489 C>T Arg497Cys b-sheet [12]
14 1603 C>T Arg535X Helical This study
F44P1 13 1489 C>T Arg497Cys b-sheet [12]
19 2150 (delC) Ala717ValfsX7 Gelsolin This study
F45P1 F45P2 2 40 C>T Arg14Trp <5% of WT expression Segment 1 [12]
9 1015 C>T Arg339X Trunk This study
F46P1 15 1733 T>C Leu578Pro Probably damaging (2.370)
c (24.06/0.74)
d Helical This study
15 1733 T>C Leu578Pro
F47P1 2 40 C>T Arg14Trp <5% of WT expression Segment 1 [12]
9–10 1109 1 5G >A – Donor site abolition (0.93>–)
e Trunk This study
F48P1 2–3 221 1 31 A>G – New donor site creation (–>0.99)
e Zink ﬁnger This study
5 367 C>T Arg123X Segment 2
F49P1 F49P2 2 40 C>T Arg14Trp <5% of WT expression Segment 1 [12]
16 1857_1859delCAT I619del Helical This study
a The nucelotides are numbered from the A of the ATG initiation codon (ENST00000377475).
b Accession number: Q15437 (UniProtKB/Swiss-Prot).
c PolyPhen prediction (PSIC score).
d PANTHER prediction (subPSEC score/Pdeleterious).
e Splice Site Prediction by Neural Network (WT sequence score > mutated sequence score).
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To date, 34 causative mutations of CDA II in SEC23B
gene were described [12–15], localized along the entire
coding sequence of the gene. Here, we described 19 novel
variants, bringing the total to 53 causative mutations
(Fig. 2A).
Figure 2B shows the relative richness of (i) distinct muta-
tions for each exon (solid line), as well as the frequency of
(ii) mutated alleles for each exon (dotted line). On the basis
of ﬁrst analysis (i), the greatest number of different muta-
tions falls in the exon 14 (13.2%), 9 and 16 (9.4%), 2 and 5
(7.5%). When we analysed the frequency of mutated alleles
for each exon (ii), we found that the largest percentage
ranks within the exons 2 (20.5%) and 4 (28.5%), as the
most frequent mutations R14W, E109K found in CDA II
patients occur within the exons 2 and 4, respectively.
Discussion
CDA II is an autosomal recessive disorder affecting the
normal differentiation-proliferation pathway of the erythroid
lineage. Up to now, 4 articles described mutations in
SEC23B gene as causative of CDA II [12–15]. Mutations
previously identiﬁed in CDA II patients (Fig. 2A) are hetero-
geneous and include frameshift, splicing, deletion, mis-
sense, and nonsense variations. In this study, we describe
28 cases from 21 unrelated families with at least one
affected proband, in which the diagnosis was made mainly
on the basis of biochemical and cytological parameters. In
almost all cases, SEC23B gene molecular analysis con-
ﬁrmed the diagnosis. We identiﬁed a total of 19 novel differ-
ent allelic variants localized along the entire coding
sequence (Fig. 2A, Table I). Most of the patients are com-
pound heterozygotes for two different mutations, while only
Figure 1. Localization and multiple-sequence alignment of mutations. Panel A. Localization of H757P, R611P, Y579N, I418M, M620V, L552F, S436L, L578P, R535X,
R339X, and R123X mutations on 3D SEC23B protein structure predicted by ESyPred3D. From N-terminal to C-terminal: zinc ﬁnger (red), trunk (yellow), b-sheet (light
blue), helical (green), and gelsolin-lile (blue) domains are shown. In grey are shown the inter-domains segments. Panel B. Six species were aligned using Database Uni-
ProtKB release 15.0 of Mar-25-2009; program NCBI BLASTP 2.0.12 (August 26, 2007) on services.uniprot.org (http: //services.uniprot.org/blast/). At the bottom, a con-
sensus line indicates conservation of the amino acid residues: an asterisk (*) indicates fully conserved sites, a colon (:) points to a conserved substitution, and a point (.)
to a semi-conserved substitution. Protein secondary structure, predicted by Jnet neural network, is also shown: alpha helix (H), beta sheet (E), or random coil (-). Dotted
lines deﬁne the domains of the protein SEC23B, according to the color scheme explained in panel A legend. Novel missense mutations are indicated with a red spot
upon the sequence at their respective amino acid positions. b. [Color ﬁgure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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research articletwo are homozygotes (F31P1, F46P1). Patients F33P1,
F37P1, F38P1, and F40P1, indeed, show only one muta-
tion (214922A >G, I418M, R339X, and L552F, respec-
tively) in the heterozygous state. However, we neither ana-
lyzed the sequence of the promoter region nor did we look
for the presence of any large DNA deletions, even if the
presence of heterozygous state of several polymorphisms
seems to exclude this possibility. As we already assumed,
we hypothesized that the elusive mutation lies in SEC23B,
because a compound heterozygosity is more likely than
two simple heterozygosities, supposing that the second
mutation stands at a different locus [14]. Our cohort of
patients showed clinical parameters consistent with what
we published before, insofar as patients carrying two mis-
sense mutations tend to be more mildly affected compared
to those with the association of one nonsense and one mis-
sense mutations [14] (Supporting Information Table Is).
Again, in no case did we ﬁnd both alleles with a nonsense
mutation. This conﬁrm that the absence of SEC23B is sup-
posed to be lethal. The pattern of these mutations empha-
sizes the high allelic heterogeneity of this condition, as
most of the variations are inherited as private mutations.
However, we also conﬁrmed that in CDA II there are recur-
ring alleles, as already demonstrated [14].
This study provided a brief description of a novel set of
SEC23B mutations in CDA II disease, localized along the
entire coding sequence and divided into: eight missense, two
frameshift, three nonsense, ﬁve splicing mutations, and one
amino acid deletion. The frameshift and nonsense mutations
result in the formation of a shorter protein with the loss of
some domains. Particularly, the nonsense c.1015 C>T
p.R339X and the frameshift c.387 (delG) p.L129LfsX26
cause the loss of part of the trunk domain, fundamental for
the interaction with the partners of the ‘‘pre-budding com-
plex,’’ Sec24 and Sar1. The causative role of the missense
changes was inferred ﬁrst by the highly evolutionary conser-
vation of the replaced residues (Fig. 1B) and then by in silico
analysis. We attempted to characterize the putative effects of
the amino acid substitutions on protein structure or function
by using PolyPhen tool. The empirically derived rules of this
web server tool predicted for all missense mutations a
‘‘probably damaging’’ effect on protein structure, i.e., they are
with high conﬁdence supposed to affect protein function or
structure (Table I). Of note, the c.2270 A>C p.H757P substi-
tution, which showed the highest PSIC score (3.488) by Poly-
Phen, is the ﬁrst mutation identiﬁed to date that fall in the
exon 20, only 10 amino acids prior to the end of the protein.
Also PANTHER conﬁrmed the probability that this variant
might have a deleterious effect on protein function, with a
Pdeleterious 5 0.78 (subPSEC 52 4.2). Since it has been al-
ready demonstrated that the most frequent mutation, c.325
G>A (p.E109K), lead to a protein instability [12], we decided
to analyze the effect of all eight missense substitution on
mRNA stability. For this purpose, we used a freeware soft-
ware program, GeneBee, in which we loaded as the input ﬁle
the full-length sequence of SEC23B mRNA, either wild type
or mutated alleles. The server predicted that only two
(c.1654 C>T p.L552F, c.1832 G>C p.R611P) out of the eight
missense mutations might to alter the secondary structure of
SEC23B mRNA when compared to that predicted for wild
type sequence. Particularly, for the c.1654 C>T (p.L552F),
the free energy of SEC23B mRNA was predicted to be higher
(2636.5 kcal/mol) when compared to that of wild type
(2640.8 kcal/mol); this value is suggestive of a reduced
mRNA stability, which could result in reduced expression of
SEC23B mRNA (Supporting Information Fig. 1s, panels A–
C). Instead, the substitution c.1832 G>C (p.R611P) seems
to confer a higher stability to mRNA secondary structure,
Figure 2. Exon allelic frequency and protein structure. Panel A. Localization of all novel mutations in bi-dimensional SEC23B protein structure. The domains are
depicted in grey and for each domain the start and the end are indicated. In the upper part, mutations described until now are indicated with symbols and colors. The red
color indicates the mutations ﬁrst described by Schwarz et al., 2009; the green color indicates those ﬁrst described by Bianchi et al., 2009; the yellow color indicates the
novel variants described by Iolascon et al., 2009; the light blue color the novel mutation described by Fermo et al., 2010. The mutations described ﬁrst in this study are
shown in dark blue. * missense mutation; h stop codon mutation; D splice site mutation, ^ frameshift mutation; amino acid deletion. Panel B. The relative richness of
single mutations in each exon (solid line) has been assessed on a total count of 53 mutations. The frequency of mutated alleles for each exon (dotted line) has been cal-
culated on an overall count of 161 mutated alleles. [Color ﬁgure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Information Fig. 1s, panel D). In the latter case, this variant
could lead to the stabilization of mRNA resulting in increased
expression of mutated allele. Of note, the free energy of our
positive control, c.325 G>A (p.E109K), was predicted to be
lower (2631.3 kcal/mol) when compared to wild type
sequence (Supporting Information Fig. 1s, panel B). Since
we did not have the availability of the cDNA of patients with
mutations close to splicing sites, we attempted to deﬁne the
effect of mutations near splice site on mRNA processing
alteration by using the web server tool, Splice Site Prediction
by Neural Network. For both variants, c.110911G >A and
c.110915G >A, the donor splice site abolition has been pre-
dicted. Instead, for the mutation c.221131 A>G was pre-
dicted the creation of a new donor splice site with a high
score (0.99).
To provide a useful information for molecular diagnosis of
CDA II, we assessed the relative richness of any distinct
mutations in each exon of SEC23B gene, as well as the fre-
quency of mutated alleles for each exon, including also the
bases ﬂanking the coding sequence. As most of the muta-
tions are the results of sporadic and independent events, we
analysed the relative richness of the single mutations for
each exon, to contribute to the improvement of the patient
management, of the molecular screening and for providing a
more aware genetic counselling. On the basis of this analy-
sis, the most richly mutated exon is the 14 (13.2%), followed
closely by exons 9 and 16 (9.4%). Of note, the exon 4, from
which the most frequently mutated alleles in CDA II patients
(E109K) stem, showed a relative richness of mutations of
only 1.9%. However, when we analysed the frequency of
mutated alleles for each exon, we found that the most fre-
quently mutated exon 4 (28.5%), closely followed by the
exon 2 (20.5%), according to the most frequent mutations
E109K and R14W (exons 4 and 2, respectively). Both these
available information could facilitate the molecular approach
in terms of exon priorities to be analyzed.
Altogether, our results extend the pattern of SEC23B
mutations associated with CDA II, propose putative models
of causality for almost all the 19 novel variants identiﬁed
and, ﬁnally, provide powerful information to improve the mo-
lecular diagnosis of CDA II.
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